F-DCFPyL PET在疑似前列腺癌患者中的诊断性能：一项系统评价和荟萃分析。

The diagnostic performance of F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis.

作者信息

Pang Wenyang, Cheng Shulin, Du Zhongbo, Du Shuang

机构信息

Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.

出版信息

Front Oncol. 2023 Mar 7;13:1145759. doi: 10.3389/fonc.2023.1145759. eCollection 2023.

INTRODUCTION

Our meta-analysis aimed to evaluate the diagnostic value of F-DCFPyL prostate-specific membrane antigen (PSMA) PET in patients with suspected prostate cancer.

METHODS

We searched for articles that evaluate the diagnostic value of F-DCFPyL PSMA PET in patients with suspected prostate cancer in PubMed, Embase, Cochrane Library, and Web of Science until 1 August 2022. Using the QUADAS-2 instrument, two researchers independently assessed the effectiveness of the studies that were included. The four-grid table data were analyzed by Meta-disc1.4 and Stata 16.0 software. The heterogeneity of each study was tested.

RESULTS

A total of five studies with 258 patients were included, and the pooled sensitivity and specificity of F-DCFPyL PSMA PET for primary prostate cancer were 0.92 (95% confidence interval (CI): 0.85-0.96) and 0.59 (95% CI: 0.08-0.96), respectively. F-DCFPyL PSMA PET was successful in detecting primary prostate cancer, with an area under the curve (AUC) of 0.92 (95% CI: 0.89-0.94).

CONCLUSIONS

F-DCFPyL PSMA PET has a strong predictive value for primary prostate cancer and is an effective method for the non-invasive diagnosis of prostate cancer. More prospective articles were needed.

引言

我们的荟萃分析旨在评估F-DCFPyL前列腺特异性膜抗原（PSMA）PET对疑似前列腺癌患者的诊断价值。

方法

我们在PubMed、Embase、Cochrane图书馆和Web of Science中检索截至2022年8月1日评估F-DCFPyL PSMA PET对疑似前列腺癌患者诊断价值的文章。使用QUADAS-2工具，两名研究人员独立评估纳入研究的有效性。采用Meta-disc1.4和Stata 16.0软件分析四格表数据。对每项研究的异质性进行检验。

结果

共纳入5项研究，涉及258例患者，F-DCFPyL PSMA PET对原发性前列腺癌的合并敏感性和特异性分别为0.92（95%置信区间（CI）：0.85-0.96）和0.59（95%CI：0.08-0.96）。F-DCFPyL PSMA PET成功检测出原发性前列腺癌，曲线下面积（AUC）为0.92（95%CI：0.89-0.94）。